[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-blood-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-blood-stem-cell-transplantation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100472787","phase-1-the-lowest-effective-dose-of-post-transplantation-cyclophosphamide-in-combination-with-sirolimus-and-mycophenolate-mofetil-as-graft-versus-host-disease-prophylaxis-after-reduced-intensity-conditioning-and-peripheral-blood-stem-cell-transplantation-100472787",false,"NCT05436418","The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","Phase I\u002FII Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","* INCLUSION CRITERIA:\n\nRecipient\n\n* Participants must have a histologically or cytologically confirmed hematologic malignancy with standard indication for allogeneic hematopoietic cell transplantation limited to one of the following:\n\n  * Acute myeloid leukemia (AML) of intermediate or adverse risk disease by the 2017 European LeukemiaNet criteria in first morphologic complete remission (\\\u003C5% blasts in the bone marrow, no detectable abnormal peripheral blasts, and no extramedullary disease)\n  * AML of any risk in second or subsequent morphologic complete remission\n  * Acute lymphoblastic leukemia in first or subsequent complete remission\n  * Myelodysplastic syndrome of intermediate or higher score by the Revised International Prognostic Scoring System (IPSS-R)\n  * Primary myelofibrosis of intermediate-2 or higher risk by the DIPSS\n  * Chronic myelomonocytic leukemia\n  * Chronic myelogenous leukemia resistant to or intolerant of \\>= 3 tyrosine kinase inhibitors or with history of accelerated phase or blast crisis\n  * B-cell lymphoma including Hodgkin lymphoma that has relapsed within 1 year of completion of primary treatment, relapsed after autologous transplantation, or has progressed through at least 2 lines of therapy\n  * Chronic lymphocytic leukemia with 17p deletion and\u002For unmutated IgHV or refractory to or intolerant of both BTK and PI3K inhibitors\n  * Mature T or NK neoplasms as defined in the WHO guidelines of sufficient type and severity for allogeneic HCT based on the Prognostic Index for T-cell lymphoma (PIT) score of low-intermediate risk or higher or on recently published clinical practice guidelines\n  * Hematologic malignancy of dendritic cell or histiocytic cell type\n  * Multiple myeloma, stage III, relapsing after therapy with both a proteasome inhibitor and an immunomodulatory drug (IMiD)\n* Age \\>= 50 years or age 18-49 years and also meeting one of the following criteria:\n\n  * Prior myeloablative HCT\n  * Prior exposure to inotuzumab, gemtuzumab, or other agent that increases the risk for sinusoidal obstruction syndrome.\n  * Hematopoietic Cell Transplantation- Comorbidity Index (HCT-CI) \\>= 3\n  * Karnofsky performance score \\\u003C80\n  * Co-morbidity considered by the treating physician to be exclusionary of myeloablative conditioning\n* At least one potentially suitable HLA-haploidentical or 10\u002F10 (HLA-A, B, C, DR, DQ) related or unrelated donor for HCT\n* Karnofsky performance score \\>= 70\n* Adequate organ function defined as possessing all of the following:\n\n  * Cardiac ejection fraction \\>= 45% by 2D ECHO;\n  * Forced expiratory volume-1 (FEV-1), forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) all of \\>= 50% predicted;\n  * Estimated serum creatinine clearance of \\>= 60 ml\u002Fminute\u002F1.73m\\^2 calculated using eGFR in the clinical lab;\n  * Total bilirubin \\\u003C= 2X the upper limit of normal;\n  * Alanine aminotransferase and aspartate aminotransferase \\\u003C= 3X the upper limit of normal.\n* Individuals of child-bearing potential (IOCBP) and participants who can father children must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least one year post-transplant.\n* IOCBP must have a negative serum or urine pregnancy test within 7 days prior to initiation of conditioning regimen.\n* Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nRecipient\n\n* Participants who are receiving any other investigational agents. Prior experimental therapies must have been completed at least 2 weeks prior to the date of beginning conditioning.\n* Active nursing.\n* Active malignancy of non-hematopoietic type (excluding non-melanoma skin cancers) which is: metastatic, or relapsed\u002Frefractory to treatment, or locally advanced and not amenable to curative treatment, or limited disease treated with curative intent treatment within the last 2 years. This excludes non-melanoma skin cancers.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents.\n* Uncontrolled intercurrent illness (e.g., severe endocrinopathy, disseminated intravascular coagulation, profound electrolyte disturbance, active infectious hepatitis, uncontrolled dental infection) that in the opinion of the Site PI would make it unsafe to proceed with transplantation.\n\nINCLUSION CRITERIA:\n\nDonor\n\n* Related (age \\>=12) and unrelated (age \\>=18) donors deemed eligible (i.e., evaluated at NIH, COH, and FHCC in accordance with existing institutional Standard Policies and Procedures or evaluated per the standards required by the IRB of the National Marrow Donor Program or applicable registry), and willing to donate research samples will be included.\n* Ability of participant or parent\u002Flegal guardian to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nDonor\n\nNone",true,"ALL","12 Years","120 Years",{"count":21,"type":22},260,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Background:\n\nBlood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Sometimes these transplants cause serious side effects, including a common immunologic problem called graft-versus-host disease. A drug called cyclophosphamide given early after the transplant (post-transplantation cyclophosphamide, PTCy) can reduce these complications. But sometimes this drug has its own negative effects. Furthermore, studies in mice suggest that an intermediate, rather than very high, dose of this drug may best protect against graft-versus-host disease.\n\nObjective:\n\nTo find out if a lower dose of PTCy is more helpful for people who undergo blood stem cell transplants.\n\nEligibility:\n\nPeople aged 18 and older who have a blood cancer and are eligible for a transplant of blood stem cells from another person. Healthy donors are also needed but must be related to the individual needing the transplant.\n\nDesign:\n\nParticipants will undergo screening. Transplant recipients will have imaging scans and tests of their heart and lung function. They will be assessed for the status of their cancer, including bone marrow taken from their pelvis and possibly also scans and\u002For fluid drawn from the spine depending on the disease type.\n\nDonors will be screened for general health. They will give several tubes of blood. They will give an oral swab and saliva and stool samples for research.\n\nRecipients will be in the hospital at least 4 to 6 weeks.\n\nThey will have a temporary catheter inserted into a vein in the chest or neck. Medications will be given and blood will be drawn through the catheter.\n\nThe transplanted stem cells will be given through the catheter. Participants will receive medications both before and after the transplant.\n\nParticipants will return to the clinic at least once a week for 3 months after leaving the hospital. Follow-up visits will continue periodically for 5 years.",[29,30],"Peripheral Blood Stem Cell Transplantation","Hematopoietic Stem Cell Transplantation",[32,33,34,35,36],"Reduced Intensity Conditioning","Systemic Immunosuppressive Therapy","Hematologic Malignancy","Acute Myeloid Leukemia","Calcineurin Inhibitor","RECRUITING","2026-06-10",{"date":40,"type":41},"2026-06-11","ACTUAL",{"date":43,"type":41},"2022-11-18",{"date":45,"type":22},"2028-06-25",{"name":47,"class":48},"National Cancer Institute (NCI)","NIH",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100446037","phase-2-ruxolitinib-and-chidamide-intensified-bucy-conditioning-regimen-100446037","NCT05088226","Ruxolitinib and Chidamide Intensified Bu\u002FCY Conditioning Regimen","Ruxolitinib and Chidamide Intensified Bu\u002FCY Conditioning Regimen for Patients With Acute B Cell Lymphoblast Leukemia Underwenting Haploidenticl Peripheral Blood Stem Cell Transplantation","Inclusion Criteria:\n\n1. high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;\n2. Have matched sibling donors, ≥8\u002F10 HLA matched unrelated donors or haploidentical donors\n3. All patients should aged 12 to 65 years;\n4. Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;\n5. Renal function: creatinine ≤the upper limit of normal;\n6. Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;\n7. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;\n8. Have signed informed consent.\n\nExclusion Criteria:\n\n1. pregnant women;\n2. Patients with mental illness or other states unable to comply with the protocol;\n3. ALL patients with Ph positive;","65 Years",{"count":59,"type":22},50,[26],"The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.",[29],"2026-04-22",{"date":65,"type":41},"2026-04-23",{"date":67,"type":41},"2021-12-01",{"date":69,"type":22},"2031-06-01",{"name":71,"class":72},"Chinese PLA General Hospital","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":73},"100513126","phase-2-eltrombopag-for-peripheral-blood-stem-cell-harvest-100513126","NCT05961410","Eltrombopag for Peripheral Blood Stem Cell Harvest","Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients With Lymphoma Undergoing Autologous Stem Cell Harvest","EPBSCH","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* Diagnosis: Hodgkin lymphoma or non-Hodgkin lymphoma\n* Disease status: complete response, partial response, or stable disease after at least 2 cycles of treatment (see appendix 2 for definition)\n* Planned to receive ESHAP (etoposide, steroid, high-dose cytarabine, cisplatin) chemotherapy with\u002Fwithout monoclonal antibody (ex: rituximab, brentuximab) as chemo-mobilization for stem cell harvest\n* East-Asian heritage\n\nExclusion Criteria:\n\n* History of vascular thromboembolic event\n* Steady state platelet count \\> 1000k\u002FμL\n* Documented cytogenetic abnormalities in marrow blood\n* Current administration of eltrombopag\n* History of grade III-IV hepatotoxicity to eltrombopag 75\u002Fmg\u002Fday\n* Life-threatening allergic reactions to eltrombopag\n* Baseline serum aspartate aminotransferase (AST), alanine aminotransferase(ALT) or total bilirubin \\> 3 fold of upper limit of normal\n* Pregnancy or breast-feeding\n* Patients with hepatitis C receiving interferon and ribavirin treatment\n* Concurrent active cancer other than lymphoma\n* Eastern Cooperative Oncology Group (ECOG) 3-4 (see appendix 4 for definition)\n* Moribund status such as concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious disease that death within 30 days is likely.\n* Inability to understand the investigational nature of the study or to give informed consent","18 Years",{"count":84,"type":22},46,[26],"The goal of this clinical trial is to explore the activity of eltrombopag in lymphoma patients receiving autologous hematopoietic stem cell harvest. The main questions it aims to answer are:\n\n* Determine the efficacy of adding eltrombopag during autologous hematopoietic stem cell mobilization and harvest.\n* Determine the pharmacokinetics and pharmacodynamics of serum eltrombopag concentration, circulating CD34+ cells during autologous hematopoietic stem cell mobilization.\n\nParticipants will receiving additional eltrombopag during stem cell harvest procedure. The amount of harvested stem cells will be compared with historical group to see if eltrombopag could increase the amount of harvested stem cells.",[88,29],"Lymphoma",[88,29],"2024-10-16",{"date":92,"type":41},"2024-10-18",{"date":94,"type":41},"2023-08-15",{"date":96,"type":22},"2026-03-01",{"name":98,"class":72},"National Taiwan University Hospital"]